Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30774529 | 0.90 | RIPK1 (0.44) | CYP11B2CYP11B1UCHL1USP30 | |
| SCHEMBL30774574 | 0.90 | CYP11B2 (0.44) | CYP11B2CYP11B1EIF2AK3UCHL1USP30 | |
| SCHEMBL30774510 | 0.90 | CYP11B2 (0.44) | CYP11B2CYP11B1UCHL1USP30SLC22A12 | |
| SCHEMBL30774460 | 0.90 | CYP11B2 (0.44) | CYP11B2CYP11B1UCHL1USP30SLC22A12 | |
| SCHEMBL30774348 | 0.87 | SMN1; SMN2 (0.49) | CYP11B2CYP11B1UCHL1USP30 | |
| SCHEMBL30774426 | 0.85 | CYP11B2 (0.48) | CYP11B2CYP11B1UCHL1USP30SLC22A12 | |
| SCHEMBL30774477 | 0.84 | EIF2AK3 (0.43) | CYP11B2CYP11B1EIF2AK3UCHL1USP30 | |
| SCHEMBL30773967 | 0.83 | NAAA (0.40) | CYP11B2CYP11B1EIF2AK3SLC22A12 | |
| SCHEMBL30774465 | 0.83 | CYP11B2 (0.46) | CYP11B2CYP11B1UCHL1USP30 | |
| SCHEMBL30774383 | 0.83 | RIPK1 (0.46) | CYP11B2CYP11B1EIF2AK3UCHL1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | claimed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | claimed |
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) | 2026-04-02 | — | — | US | disclosed |
| EP-4574830-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Guangzhou Vinnocent Pharmaceutical Limited (CN) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024061371-A1 | ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 广州威诺森医药科技有限公司 | 2024-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092074-A1 | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof | STS, NR5A1, CYP21A2 | CYP11B2 38/4885CYP11B1 23/4885EIF2AK3 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.